跳转至内容
Merck
CN

SML2303

Sigma-Aldrich

Tosedostat

≥98% (HPLC)

别名:

2S-[2R-(S-Hydroxy-hydroxycarbamoyl-methyl)-4-methylpentanoyl-amino]-2-phenylethanoic acid cyclopentyl ester, CHR-2797

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C21H30N2O6
化学文摘社编号:
分子量:
406.47
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

CC(C)C[C@H]([C@H](O)C(NO)=O)C(N[C@@H](C1=CC=CC=C1)C(OC2CCCC2)=O)=O

InChI

1S/C21H30N2O6/c1-13(2)12-16(18(24)20(26)23-28)19(25)22-17(14-8-4-3-5-9-14)21(27)29-15-10-6-7-11-15/h3-5,8-9,13,15-18,24,28H,6-7,10-12H2,1-2H3,(H,22,25)(H,23,26)/t16-,17+,18+/m1/s1

InChI key

FWFGIHPGRQZWIW-SQNIBIBYSA-N

生化/生理作用

Potent cell permeable, antiproliferative aminopeptidase inhibitor
Tosedostat (CHR-2797) is a potent cell permeable, antiproliferative aminopeptidase inhibitor. It has been in clinical trials for AML, pancreatic cancer and more.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Caner Saygin et al.
Journal of hematology & oncology, 10(1), 93-93 (2017-04-20)
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely unchanged in the past 40 years. However, various novel agents have demonstrated clinical activity, either
Raya Mawad et al.
British journal of haematology, 172(2), 238-245 (2015-11-17)
Tosedostat, an oral aminopeptidase inhibitor, has synergy with cytarabine and hypomethylating agents. We performed a Phase II trial to determine rates of complete remission (CR) and survival using tosedostat with cytarabine or decitabine in older patients with untreated acute myeloid
Danielle Shafer et al.
Blood reviews, 30(4), 275-283 (2016-03-15)
Acute myeloid leukemia (AML) remains a challenge to both patients and clinicians. Despite improvements in our understanding of the disease, treatment has changed minimally and outcomes remain poor for the majority of patients. Within the last decade, there have been

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持